All studies · Recovery · Viral clearance · RCTs · Peer-reviewed · All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−1%

Viral clearance (1)−39%

RCTs (1)−1%

Early (1)−1%

00.511.5+

← Pomotrelvir
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

Pomotrelvir COVID-19 studies

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Borroto-.. (DB RCT)−1%1.01 · 0.50–2.04no recov.20/15310/77

Early treatment−1%1.01 · 0.50–2.0420/15310/771% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.99

All studies−1%1.01 · 0.50–2.0420/15310/771% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.9900.511.52+

Rotate screen for more detailsIncrease width for more details

← Pomotrelvir
reduces riskPomotrelvir
increases risk →

Pomotrelvir COVID-19 recovery results

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Borroto-.. (DB RCT)−1%1.01 · 0.50–2.04no recov.20/15310/77

Early treatment−1%1.01 · 0.50–2.0420/15310/771% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.99

All studies−1%1.01 · 0.50–2.0420/15310/771% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.9900.511.52+

Rotate screen for more detailsIncrease width for more details

← Pomotrelvir
reduces riskPomotrelvir
increases risk →

Pomotrelvir COVID-19 viral clearance results

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Borroto-.. (DB RCT)−39%1.39 · 0.15–12.97viral+3/841/39

Early treatment−39%1.39 · 0.15–12.973/841/3939% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.78

All studies−39%1.39 · 0.15–12.973/841/3939% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.7800.511.52+

Rotate screen for more detailsIncrease width for more details

← Pomotrelvir
reduces riskPomotrelvir
increases risk →

Pomotrelvir COVID-19 Randomized Controlled Trials

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Borroto-.. (DB RCT)−1%1.01 · 0.50–2.04no recov.20/15310/77

Early treatment−1%1.01 · 0.50–2.0420/15310/771% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.99

All studies−1%1.01 · 0.50–2.0420/15310/771% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.9900.511.52+

Rotate screen for more detailsIncrease width for more details

← Pomotrelvir
reduces riskPomotrelvir
increases risk →

Pomotrelvir COVID-19 peer reviewed studies

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Borroto-.. (DB RCT)−1%1.01 · 0.50–2.04no recov.20/15310/77

Early treatment−1%1.01 · 0.50–2.0420/15310/771% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.99

All studies−1%1.01 · 0.50–2.0420/15310/771% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.9900.511.52+

Rotate screen for more detailsIncrease width for more details

← Pomotrelvir
reduces riskPomotrelvir
increases risk →

Pomotrelvir COVID-19 outcomes

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Borroto-.. (DB RCT)−1%1.01 · 0.50–2.04no recov.20/15310/77 Borroto-.. (DB RCT)−6%1.06 · 0.52–2.13no recov.21/15310/77 Borroto-.. (DB RCT)4%0.96 · 0.49–1.89no recov.21/15311/77 Borroto-.. (DB RCT)−252%3.52 · 0.82–15.11misc.14/1532/77 Borroto-.. (DB RCT)−39%1.39 · 0.15–12.97viral+3/841/39 Borroto-.. (DB RCT)−15%1.15 · 0.79–1.67viral+47/8419/39

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Pomotrelvir
reduces riskPomotrelvir
increases risk →

Most accessed treatments

Antiviral effects

Vitamins & Minerals

Host endosomal entry / trafficking

Dual-action mAbs

RdRp

Nasal & Oral Sprays / Rinses

Analgesics

Antiandrogens

Host targets and pathways

Inflammatory and immune modulation

Mpro (Gen 1)

Oxidative stress and cytoprotection

Lifestyles

TMPRSS2

Spike neutralization

Replication inhibition (target unresolved)

COVID-19 mAbs

Pleiotropic modulation

Attachment / entry inhibition

Mpro (Gen 2)

H1RAs

Nutrients and microbiome support

Host mAbs

IL-6 / IL-6R blockade

Physical and extracorporeal interventions

Natural products and extracts

Symptom management

Unconfirmed antiviral rationale

Lifestyle, behaviors, and exposure prevention

Other complication management

Mpro / 3CLpro

Host pyrimidine synthesis

Direct viral inactivation

Endothelial / vascular protection

Direct respiratory tract treatments

Other antibodies, proteins, peptides, cells, and RNA therapies

Secondary infection and coinfection management

Pomotrelvir: meta-analysis of COVID-19 studies

Pomotrelvir COVID-19 studies

Pomotrelvir COVID-19 recovery results

Pomotrelvir COVID-19 viral clearance results

Pomotrelvir COVID-19 Randomized Controlled Trials

Pomotrelvir COVID-19 peer reviewed studies

Pomotrelvir COVID-19 outcomes